• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Glaukos Corporation

    4/16/26 6:02:11 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care
    Get the next $GKOS alert in real time by email
    DEFA14A 1 gkos_defa_14a_naa_2026.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Under §240.14a-12

     

     

     

     

    GLAUKOS CORPORATION

    (Name of Registrant as Specified In Its Charter)

     

     

     

     

    Not applicable

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

     

     

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


     

     

    img68542912_0.jpg

    Your Vote Counts! GLAUKOS CORPORATION 2026 Annual Meeting Vote by May 27, 2026 11:59 PM ET GLAUKOS CORPORATION ONE GLAUKOS WAY ALISO VIEJO, CA 92656 You invested in GLAUKOS CORPORATION and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 28, 2026. Get informed before you vote View the Notice & Proxy Statement, Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 14, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Smartphone users Point your camera here and vote without entering a I number Virtually at: Vote Virtually at the Meeting* May 28, 2026 9:00 AM PDT www.virtualshareholdermeeting.com/GKOS2026 *Please check the meeting materials for any special requirements for meeting attendance.

     

     


     

     

    img68542912_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. Election of Directors Nominees:01) Denice M. Torres 02) Aimee S. WeisnerBoard Recommends 2.Approval, on an advisory basis, of the compensation of the Company's named executive officers. 3.Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. For For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting and any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

     

     


    Get the next $GKOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GKOS

    DatePrice TargetRatingAnalyst
    10/27/2025$120.00Equal Weight → Overweight
    Wells Fargo
    10/1/2025$103.00Buy
    Goldman
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    12/6/2024$182.00Buy
    UBS
    12/2/2024$120.00Equal-Weight → Underweight
    Morgan Stanley
    7/10/2024$132.00Buy → Neutral
    Citigroup
    More analyst ratings

    $GKOS
    SEC Filings

    View All

    SEC Form DEF 14A filed by Glaukos Corporation

    DEF 14A - GLAUKOS Corp (0001192448) (Filer)

    4/16/26 6:01:06 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Glaukos Corporation

    DEFA14A - GLAUKOS Corp (0001192448) (Filer)

    4/16/26 6:02:11 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Glaukos Corporation

    SCHEDULE 13G/A - GLAUKOS Corp (0001192448) (Subject)

    3/26/26 6:39:02 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glaukos Announces the Release of its 2025 Sustainability Report

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website here. "I am proud to issue our seventh annual Sustainability Report, which highlights the meaningful progress we continue to make in advancing our core corporate sustainability initiatives that are aligned with our mission and key strategic plans," said

    4/16/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Receives Permanent J-code for Epioxa™

    New J-code for Epioxa™, J2789, set to become effective July 1, 2026 Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ ("Epioxa") for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated. The new J-code for Epioxa, J2789, is set to become effective July 1, 2026. It is expected to streamline the

    4/15/26 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (

    4/8/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Navratil Tomas

    4 - GLAUKOS Corp (0001192448) (Issuer)

    4/14/26 4:07:03 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Navratil Tomas

    4 - GLAUKOS Corp (0001192448) (Issuer)

    4/3/26 9:25:57 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Thurman Alex R.

    4 - GLAUKOS Corp (0001192448) (Issuer)

    4/3/26 9:22:14 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Glaukos upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Glaukos from Equal Weight to Overweight and set a new price target of $120.00

    10/27/25 8:30:13 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Glaukos with a new price target

    Goldman initiated coverage of Glaukos with a rating of Buy and set a new price target of $103.00

    10/1/25 8:52:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

    5/1/25 7:44:23 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IDOSE TR issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/15/23 11:41:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    FDA Approval for TRAVOPROST issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/14/23 7:41:03 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Leadership Updates

    Live Leadership Updates

    View All

    OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

    1/4/23 8:00:00 AM ET
    $BLU
    $GKOS
    $INSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

    Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

    12/20/21 4:15:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

    3/1/21 4:10:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Financials

    Live finance-specific insights

    View All

    Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (

    4/8/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis. Glaucoma record net sales of $119.2 million in Q4 2025 increased 42% year-over-year. U.S. Glaucoma record net sales of $86.4 million in Q4 2025 increased 53% year-over-year. Net sales of $507.4 million in 2025 increased 32% yea

    2/17/26 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2025 financial results after the market close on Tuesday, February 17, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.)

    1/20/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    11/14/24 1:21:45 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/14/24 3:55:55 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/13/24 5:41:34 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care